stars 1 stars 2 stars 3

Scantox is a preclinical GLP-accredited CRO, specialized in providing services within the drug development process Discovery, Genetic Toxicology, Regulatory Toxicology and Pharmaceutical Development & Analytical. Based on decades of experience, we are a trusted partner for CRO services for the pharmaceutical and medical devices industries. The Scantox Group is headquartered in Ejby, Denmark, with subsidiaries in UK, Austria, Denmark and Sweden (Lund and Gothenburg). The Scantox services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. The Scantox team is passionate about the common vision to improve the health of people, and all processes are rooted in dedication and guided by a strong sense of purpose. Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo. Certified as a 2023 Great Place To Work™. #pharmacology #toxicology #histopathology #pathology #minipigtoxicology #neuropharmacology #genotox

Scantox Group Questions

The Scantox Group annual revenue was $6.2 million in 2026.

Jeanet Løgsted is the CEO of Scantox Group.

128 people are employed at Scantox Group.

Scantox Group is based in Lille Skensved, Zealand.

The NAICS codes for Scantox Group are [621, 62].

The SIC codes for Scantox Group are [807, 80].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users